A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune SystemSafety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent InfectionsA Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male SubjectsImpact of Oral Antibiotic Treatment on C. DifficileEfficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile InfectionStudy to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older PopulationA Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus VancomycinA Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian SubjectsSafety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the PathogenesisFidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile InfectionDoes Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord InjuryDescription of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These PatientsFidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)Optimal Treatment for Recurrent Clostridium DifficilePAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile InfectionA Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)Fecal Microbiota Transplantation for Relapsing Clostridium Difficile InfectionEvaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
P4844
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infectionsReduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycinCharacterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanDecreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.Clostridium difficile infection in older adults: a review and update on its management.Fidaxomicin for the treatment of Clostridium difficile infections.Fidaxomicin, a new treatment for Clostridium difficile infections.Fidaxomicin: a new option for the treatment of Clostridium difficile infection.Antimicrobial activities of fidaxomicinFidaxomicin is an inhibitor of the initiation of bacterial RNA synthesisFidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
P921
Q63834635-67F29D1B-038A-4DB9-AF4D-4699EFDEDCC3Q63843793-E1CBDFA1-56EF-46EB-AFA6-9462F8751B0AQ64188282-7E994998-4F4D-4035-90E3-483248401992Q64221610-1F5FB877-81A8-4B51-86E5-B95C38958078Q64336146-A165A0D3-C12A-4C57-B2DD-EBA0B5FD5BD7Q64395528-2249AD19-677F-4F68-A8FE-38837FC7CD87Q64397249-2D3B0055-AFD5-4958-907A-3EF5866DA24AQ64601749-DAF53923-AE26-4091-AB6E-FA3AC2683706Q64604576-8615BD52-B5B7-411A-A615-AD47168F360CQ64610627-DD251129-0676-4C73-AC82-EF94F9876FBEQ64625335-EE95E639-2494-4FCC-97D8-5881645BA1F9Q64631895-43BD1CD8-D5E4-453C-B8EE-5EFD65A9D70DQ64640945-F5ECA9B8-08D0-48DF-A6AE-89358BD6B9B2Q64672550-035281B0-055E-47CA-8D7A-1E6AE454CF61Q65346402-A59583EE-FE83-4437-B89F-ED4E6197C661Q65346795-A0BCEF32-390B-43EE-8347-52B1C276D50CQ65349496-91C51AEC-E821-40D1-82D7-42C32C289EC1Q65352335-686427C6-D5AA-4A09-8293-DA9CD0ACFE01Q65391228-32520562-3664-436E-95F3-9FAFE6E54A04Q65465537-B387759B-63D5-4755-99F6-31AC53FB323CQ65471413-9EABABDC-20FE-4F4E-9246-5F1178A2F21DQ66072727-8BD0DA35-532C-4D38-BD5D-42BE61BE9711Q66403204-54AA8F71-73BE-4E40-80BF-0FEC3EFCE617Q66405850-9F5A7F80-BAF0-485B-BE00-73721C03721DQ74287092-C4A6AD14-EB78-489D-94A6-09031F30EF71
P4844
Q30425705-E4179815-7435-4B3C-AB3F-ED67FB19DE4AQ34030436-83B5285C-C3CA-482D-97B5-16702B1077E1Q34276090-EA2064BF-19FE-4B2D-AFC5-8821B481B780Q34306091-14C488E3-E7F6-4BB0-87C3-288FD46AD532Q35941496-041806B7-6E8E-4446-BC30-1BF31E82E71BQ36071501-3C1323AD-28D5-4E60-AF74-6896AA17C2F7Q36071504-36F273AC-D175-4BEB-A6A8-AA31CCB1234BQ36071516-BA5B9149-801D-4917-89C8-751BCB3A6840Q36071520-A0292381-A7F7-41F9-9F8C-FA61324AFBC5Q36071524-B6F5A85F-50E3-4C60-AE3D-207E9F912C90Q36086377-110D187A-D876-47C5-A0C1-86CFD64F0B24Q36379411-20E92BA5-9FA8-499F-9E91-B25A1B8392BAQ37092512-964AFD7E-918F-4268-9889-2804A0FD2D13Q37966763-2D9BCD81-5B8A-4551-926A-4EE00C665836Q37977204-4C8B305D-D1E2-48E3-A020-6FBF0D66C0E0Q37982679-B1B68EA7-D454-4924-B2FA-2BBD5B4FD0E4Q37989945-D5CFA057-E3A2-4F4D-8111-0D298DBF3B95Q38032240-CDCEBBF1-D1B2-476F-BA35-5F6C8CAB209FQ42222510-16E9E594-A6F6-4FA9-A288-6C2EAEED01BAQ42222521-2DD0E486-79A0-45DC-9AD3-B4B50B68A09EQ59831521-7DD9EE37-AA54-4FC1-9651-6CFA18C08663Q61647235-91E49B83-6C2C-4E5D-8D2A-C8147F896F26Q61713430-6C686BDD-E93B-458F-887C-BAA494FF5ED6
P921
description
Arzneistoff
@de
chemická sloučenina
@cs
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
compuesto quimico
@an
name
Fidaksomicin
@sh
Fidaksomicin
@sr
Fidaksomisiini
@fi
Fidaxomicin
@de
Fidaxomicin
@en-ca
Fidaxomicin
@en-gb
Fidaxomicin
@hu
Fidaxomicine
@nl
fidaxomicin
@en
fidaxomicina
@it
type
label
Fidaksomicin
@sh
Fidaksomicin
@sr
Fidaksomisiini
@fi
Fidaxomicin
@de
Fidaxomicin
@en-ca
Fidaxomicin
@en-gb
Fidaxomicin
@hu
Fidaxomicine
@nl
fidaxomicin
@en
fidaxomicina
@it
altLabel
Dificid
@en
Difimicin
@en
Lipiarmicin
@en
Lipiarmycin
@en
Lipiarrmycin
@en
OPT 80
@en
OPT-80
@en
PAR 101
@en
PAR-101
@en
Tiacumicin B
@en
prefLabel
Fidaksomicin
@sh
Fidaksomicin
@sr
Fidaksomisiini
@fi
Fidaxomicin
@de
Fidaxomicin
@en-ca
Fidaxomicin
@en-gb
Fidaxomicin
@hu
Fidaxomicine
@nl
fidaxomicin
@en
fidaxomicina
@it
P592
P6366
P661
P662
P665
P683
P2017
CC[C@H]1/C=C(/[C@H](C/C=C/C=C( ...... =C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\C
P2067
P2115
N0000182832
P2275
Fidaxomicin
@en
P231
873857-62-6